What are your top takeaways in Head & Neck Cancers from ASCO 2025?

The phase 3 KEYNOTE-689 and the phase 3 NIVOPOSTOP. A key distinction is that KEYNOTE-689 incorporated both neoadjuvant and adjuvant immunotherapy, while NIVOPOSTOP restricted immunotherapy to the adjuvant phase and specifically targeted patients with high-risk features (+ margins and ECS) post-surg...

ASCO 2025 had several interesting abstracts for head and neck cancers. The following abstracts could reshape the landscape of locally advanced head and neck squamous cell carcinoma by finally showing improvement in outcomes with PD-1 inhibitors in the curative setting. Hopefully, these trials mark t...

ASCO 2025 included several interesting presentations regarding the role of
immunotherapy in the primary therapy of HNC, skin squamous, CCA, and NPC. While Immunotherapy has been established as first-line therapy in R/M HNC, its role in the primary therapy has not yet been clear.

Phase III studies like...